newsfilter
← Latest News
GlobeNewswire·

HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

  • HUTCHMED announced preclinical data for HMPL-A830, a first-in-class EGFR-directed Antibody-Targeted Therapy Conjugate (ATTC) with a pan-KRAS inhibitor payload, at the EORTC-NCI-AACR International Conference in Barcelona on November 18, 2026.
  • HMPL-A830 combines an anti-EGFR antibody with a selective KRAS small molecule inhibitor to simultaneously block EGFR signaling & KRAS activity in both ON & OFF states.
  • In vitro studies showed potent antiproliferative activity across 55 tumor cell lines with diverse KRAS mutations (including G12C, G12D, G12V, G13D) & wild-type amplifications.
  • The drug demonstrated rapid internalization into EGFR-positive cells, a strong bystander killing effect on neighboring EGFR-negative tumor cells, & robust antibody-dependent cellular cytotoxicity (ADCC) activity.
  • Mouse model studies revealed dose-dependent tumor regressions that were more durable than those achieved by KRAS G12C inhibitors & outperformed comparative regimens including unconjugated antibodies & other antibody-drug conjugates.
  • Pharmacokinetic analysis confirmed sustained inhibition of EGFR/KRAS downstream signaling & a stable drug-to-antibody ratio across mouse, monkey, & human plasma.
  • HUTCHMED entered an exclusive development & license agreement with a GSK subsidiary in September 2026, granting GSK worldwide rights outside Mainland China, Hong Kong, Macau, & Taiwan.
  • HUTCHMED will lead the global Phase I development program, while the GSK subsidiary will handle subsequent clinical development & commercialization outside the specified Asian regions.
  • A global Phase I trial (NCT07718581) is currently evaluating HMPL-A830 in patients with unresectable, advanced, or metastatic solid tumors.
  • The ATTC platform aims to overcome on-target, off-tumor toxicity associated with systemic small molecule inhibitors by delivering payloads directly to EGFR-expressing tumors.
  • KRAS mutations are prevalent in approximately 44% of colorectal cancer, 34% of lung adenocarcinoma, & up to 89% of pancreatic ductal adenocarcinoma patients.
  • EGFR upregulation is identified as a key mechanism of acquired resistance to KRAS-targeted therapies, providing a rationale for dual EGFR/KRAS targeting.
Company
HUTCHMED (China) Limited
Keywords
Nasdaq:HCM, HUTCHMED (China) Limited